Dinutuximab beta

达妥昔单抗β

Report date: 2025/06/16 16:57:35

Base Information

Drug NameDinutuximab beta
Drug Alias Name迪妥昔单抗QarzibaIsqetteAPN-311ch14.18/CHO
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsNeuroblastoma
Global Approved IndicationsNeuroblastoma
Approved Indications in ChinaNeuroblastoma
Original Approved Country/TerritoryEU
Original Approved Date2017/05/08
Country/TerritoryMainland China(BOAO LECHENG)PolandNetherlands +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChildren'S Cancer Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesRecordati Netherlands BVEusa PharmaApeiron Biologics +[6] 
Inactive CompaniesEusa Pharma (Netherlands) BvCharite University, Berlin, GermanyUniversity Medicine Greifswald +[6] 
Active IndicationsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeL01XC16
Related LinksWikipediaDrugBank